Share
.webp)
.webp)
.webp)
.webp)
Guy Oliver
Bristol Myers Squibb is pleased to announce the appointment of Guy Oliver as the new General Manager for its UK and Ireland operations.
In this role, Guy will lead the commercial affiliate during a transformative phase, focusing on expanding the company’s product portfolio to advance its mission of helping patients overcome serious diseases. Guy will also serve on the European Markets Leadership Team, reporting directly to Monica Shaw, Senior Vice President and Head of European Markets.
Expressing his enthusiasm for the role, Guy said, "I’m thrilled to be joining Bristol Myers Squibb at such an exciting juncture. I look forward to collaborating with the team to achieve our ambitious goals of delivering more life-changing medicines to patients across the UK and Ireland. Bristol Myers Squibb's recognition as a Great Place to Work® UK showcases its commitment not only to patients but also to its talented workforce. I am eager to contribute to a thriving, inclusive culture where we can inspire and empower each other to accomplish great things."
Guy Oliver brings a wealth of experience from his previous role as General Manager for Ipsen UK and Ireland. Prior to Ipsen, he spent 16 years at Novartis, where he held various senior leadership roles across multiple functions and regions. His background includes significant expertise in therapeutic areas such as oncology, hematology, immunology, cardiovascular, and neuroscience. He holds degrees in Pharmacology and Pharmacy and began his career as a Pharmacist in New Zealand, later serving as a Clinical Pharmacist at Guy’s Hospital in London before transitioning into the pharmaceutical industry.
Monica Shaw, Senior Vice President of European Markets at Bristol Myers Squibb, stated, "We are delighted to welcome Guy at this crucial time as we expand our portfolio of innovative medicines. Guy’s passion for accelerating access to breakthrough therapies makes him the ideal leader to carry out our mission of helping patients prevail over serious diseases."
